6CM
VOR icon

683 Capital Management’s Vor Biopharma VOR Stock Holding History

683 Capital Management’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,271
Closed -$137K – 253
2023
Q1 		$137K Hold
1,271
– – 0.01% 215
2022
Q4 		$169K Buy
+1,271
New +$126K 0.01% 205

Other funds holding VOR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

683 Capital Management's VOR Position: Q2 2023 in Review

683 Capital Management sold out of Vor Biopharma (VOR) in Q2 2023, closing a stake of 1,271 shares — an estimated $137K sold.

683 Capital Management first reported a position in VOR in Q4 2022 and held it in 2 quarters. The position peaked at $169K in Q4 2022. 71 funds tracked by Wall St. Rank hold VOR as of Q2 2023.

  • 683 Capital Management reported no remaining Vor Biopharma position as of Q2 2023 after selling out during the quarter.
  • 683 Capital Management sold 1,271 Vor Biopharma shares in Q2 2023, an estimated $137K.
  • 683 Capital Management first reported a position in Vor Biopharma in Q4 2022 and held it in 2 quarters.
  • 683 Capital Management's Vor Biopharma position peaked at $169K in Q4 2022.
  • 71 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2023.

Based on 683 Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.